Signal transduction in prostate cancer progression.

@article{Gioeli2005SignalTI,
  title={Signal transduction in prostate cancer progression.},
  author={Daniel Gioeli},
  journal={Clinical science},
  year={2005},
  volume={108 4},
  pages={
          293-308
        }
}
  • D. Gioeli
  • Published 1 April 2005
  • Medicine, Biology
  • Clinical science
Prostate cancer is the most frequently diagnosed cancer among men and the second leading cause of male cancer deaths in the United States. When prostate cancer initially presents in the clinic, the tumour is dependent on androgen for growth and, therefore, responsive to the surgical or pharmacological ablation of circulating androgens. However, there is a high rate of treatment failure because the disease often recurs as androgen-independent metastases. Surprisingly, this late-stage androgen… 
View on PubMed
clinsci.org
120 Citations
Highly Influential Citations
8
Background Citations
51
Methods Citations
1

120 Citations

Citation Type

Citation Type

Androgen receptor action in hormone‐dependent and recurrent prostate cancer
TLDR
It is proposed that AR continues to play a role in many of these tumors and that it is not only the levels of AR, ligands, and co‐regulators, but also the changes in cell signaling that induce AR action in recurrent prostate cancer are potential therapeutic targets.
Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.
TLDR
It is proposed that CHK2 is a negative regulator of androgen sensitivity and prostate cancer growth, and thatCHK2 signaling is lost during prostate cancer progression to castration resistance, and perturbing CHK1 signaling may offer a new therapeutic approach for sensitizing CRPC to ADT and radiation.
Identification of Kinases Regulating Prostate Cancer Cell Growth Using an RNAi Phenotypic Screen
TLDR
This study demonstrates the applicability of lentiviral-based shRNA for conducting phenotypic screens and identifies MAP3K11, DGKD, ICK, CIT, GALK2, and PSKH1 as regulators of prostate cancer cell growth.
Androgen Receptor Coregulators and Their Role in Prostate Cancer
TLDR
This chapter focuses on a subset of the most well-characterized AR coregulators that are associated with prostate cancer, and the mechanisms by which classical type I and nonclassical type II AR coactivators/corepressors regulate AR transcriptional activity.
The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor.
TLDR
It is shown that neuroendocrine-derived parathyroid hormone-related protein (PTHrP)-mediated signaling through the epidermal growth factor receptor (EGFR) and Src pathways contributes to the phenotype of advanced prostate cancer by reducing AR protein turnover.
The power and promise of “rewiring” the mitogen-activated protein kinase network in prostate cancer therapeutics
TLDR
The current knowledge regarding the involvement of the Ras/MAPK pathway in prostate carcinogenesis is delineated, ongoing research concerning the development of novel targeted agents in prostate cancer is spotlighted, and the future perspectives of their therapeutic efficacy are discussed.
Anti-androgen resistance in prostate cancer cells chronically induced by interleukin-1β.
TLDR
Interestingly, in cells subjected to chronic interleukin-1β stimulation, the transcription of the androgen receptor gene is restored within a few cell passages and the cells acquire the ability to grow in the presence of the anti-androgen, bicalutamide.
Current perspectives in the treatment of advanced prostate cancer
TLDR
Novel pharmaceutical compounds and innovative approaches, integrated into the concept of individualized therapy will hopefully, during the next decade, improve the outcome and survival for hundreds of thousands of men worldwide.
Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer
TLDR
It is proposed that androgen independence emerges by means of epithelial–stromal competition, in which activation of Akt and Erk promotes AR activity in the prostate epithelium while counteracting antagonistic effects of the stroma.
Molecular genetics of prostate cancer: new prospects for old challenges.
TLDR
An overview of major themes in prostate cancer research is presented, focusing on current knowledge of principal events in cancer initiation and progression, including new insights into the mechanisms of castration resistance, identification of stem cells and tumor-initiating cells, and development of mouse models for preclinical evaluation of novel therapuetics.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 172 REFERENCES
Androgen receptor signaling in androgen-refractory prostate cancer.
TLDR
This review seeks to identify specific molecular events that may be linked directly to the progression to androgen-refractory prostate cancer and identifies mechanisms that appear to involve the androgen receptor (AR).
Ras signaling in prostate cancer progression
TLDR
It is argued that growth factors and receptors that utilize Ras family members drive prostate cancer progression to a state of androgen hypersensitivity; and that post‐translational modifications (e.g., phosphorylations) of transcriptional cofactors might be responsible for modulating the function of the AR so that it is active even at low concentrations of androgens.
The role of androgens and the androgen receptor in prostate cancer.
Androgen receptor – an update of mechanisms of action in prostate cancer
TLDR
Current research efforts are focused on elucidation of function of AR coregulatory proteins, coactivators and corepressors to serve as a basis for a more efficient pharmacological inhibition of the AR in advanced carcinoma of the prostate.
The role of the androgen receptor in prostate cancer.
TLDR
Evaluating the significance of the AR in the development and progression of prostate cancer results in an abnormal profile of AR-regulated genes, which include cell cycle regulators, transcription factors, and those proteins important for cell survival, lipogenesis, and secretion.
Androgen receptors in prostate cancer.
TLDR
AR is functional in advanced carcinoma of the prostate, as evidenced in studies of mutant receptors and ligand independent activation, and AR coactivator complexes might be a target for novel therapies for prostate cancer.
Her-2-neu expression and progression toward androgen independence in human prostate cancer.
TLDR
Her-2-neu expression appears to increase with progression to androgen independence, and therapeutic targeting of this tyrosine kinase in prostate cancer may be warranted.
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?
TLDR
Prostate cancers should provide a paradigm for successful rational drug development based on this unique therapeutic index because blocking AR signaling while eliminating the metastatic prostate cancer cells remaining after androgen ablation would not be life threatening.
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.
TLDR
A majority of recurrent prostate cancers express high levels of the androgen receptor and two nuclear receptor coactivators, transcriptional intermediary factor 2 and steroid receptors coactivator 1, and this work provides a molecular basis for this activation and suggests a general mechanism for recurrent prostate cancer growth.
Distant metastases from prostatic carcinoma express androgen receptor protein.
TLDR
Evidence is provided that, unlike androgen-independent prostatic carcinoma cell lines, distant prostate cancer metastases do express the androgen receptor (AR) protein, which indicates that the AR may be involved in the progression of prostate cancer.
...
1
2
3
4
5
...